Literature DB >> 10468288

Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.

A Evrard1, P Cuq, J Ciccolini, L Vian, J P Cano.   

Abstract

5-Fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-FU, are anticancer agents activated by thymidine phosphorylase (TP). Transfecting the human TP cDNA into cancer cells in order to sensitize them to these pyrimidine antimetabolites may be an important approach in human cancer gene therapy research. In this study, an expression vector containing the human TP cDNA (pcTP5) was transfected into LS174T human colon carcinoma cells. Eight stable transfectants were randomly selected and analysed. The cytotoxic effects of 5-FU and 5'-DFUR were higher in TP-transfected cells as compared to wild-type cells. The maximal decreases in the IC50 were 80-fold for 5-FU and 40-fold for 5'-DFUR. The increase in sensitivity to these pyrimidines of TP-transfected cells significantly correlated with the increase in both TP activity and TP expression. Transfected clone LS174T-c2 but not wild-type cells exhibited formation of [3H]FdUMP from [3H]5-FU. In addition the LS174T-c2 clone enhanced the cytotoxic effect of 5'-DFUR, but also that of 5-FU, towards co-cultured parental cells. For both anti-cancer agents, this bystander effect did not require cell-cell contact. These results show that both 5-FU or 5'-DFUR could be used together with a TP-suicide vector in cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468288      PMCID: PMC2363120          DOI: 10.1038/sj.bjc.6690589

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  46 in total

1.  5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.

Authors:  U Lönn; S Lönn; U Nylen; G Winblad
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.

Authors:  L Elias; H A Crissman
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

4.  Pentosyl transfer mechanisms of the mammalian nucleoside phosphorylases.

Authors:  T A Krenitsky
Journal:  J Biol Chem       Date:  1968-06-10       Impact factor: 5.157

5.  Catabolism of thymidine in human blood platelets: purification and properties of thymidine phosphorylase.

Authors:  C Desgranges; G Razaka; M Rabaud; H Bricaud
Journal:  Biochim Biophys Acta       Date:  1981-07-27

6.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

7.  Purification and properties of an endothelial cell growth factor from human platelets.

Authors:  K Miyazono; T Okabe; A Urabe; F Takaku; C H Heldin
Journal:  J Biol Chem       Date:  1987-03-25       Impact factor: 5.157

8.  The role of blood platelets in nucleoside metabolism: regulation of platelet thymidine phosphorylase.

Authors:  T Shaw; R H Smillie; A E Miller; D G MacPhee
Journal:  Mutat Res       Date:  1988 Jul-Aug       Impact factor: 2.433

9.  Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine.

Authors:  H Ishitsuka; M Miwa; K Takemoto; K Fukuoka; A Itoga; H B Maruyama
Journal:  Gan       Date:  1980-02

10.  Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.

Authors:  J L Grem; P H Fischer
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  21 in total

1.  Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.

Authors:  Roshawn G Watson; Filipe Muhale; Leigh B Thorne; Jinsheng Yu; Bert H O'Neil; Janelle M Hoskins; Michael O Meyers; Allison M Deal; Joseph G Ibrahim; Michael L Hudson; Christine M Walko; Howard L McLeod; James T Auman
Journal:  Eur J Cancer       Date:  2010-08-18       Impact factor: 9.162

2.  Transfection of thymidine phosphorylase cDNA to human hepatocellular carcinoma cells enhances sensitivity to fluoropyrimidine but augments endothelial cell migration.

Authors:  Jian Zhou; Yong-Sheng Xiao; Zhao-You Tang; Jia Fan; Zhi-Quan Wu; Yan Zhao; Qiong Xue; Zao-Zhuo Shen; Yin-Kun Liu; Sheng-Long Ye
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-30       Impact factor: 4.553

3.  5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.

Authors:  Jin-Fang Zheng; Hai-Dong Wang
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

4.  Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.

Authors:  Weijun Wang; Chien-Kuo Tai; Allan D Kershaw; Sounkary K Solly; David Klatzmann; Noriyuki Kasahara; Thomas C Chen
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

5.  In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity.

Authors:  Raphaelle Fanciullino; Séverine Mollard; Sarah Giacometti; Yael Berda-Haddad; Mohamed Chefrour; Claude Aubert; Athanassios Iliadis; Joseph Ciccolini
Journal:  Pharm Res       Date:  2013-02-06       Impact factor: 4.200

6.  Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.

Authors:  Caroline Raynal; Jean-Marc Pascussi; Géraldine Leguelinel; Cyril Breuker; Jovana Kantar; Benjamin Lallemant; Sylvain Poujol; Caroline Bonnans; Dominique Joubert; Frédéric Hollande; Serge Lumbroso; Jean-Paul Brouillet; Alexandre Evrard
Journal:  Mol Cancer       Date:  2010-03-02       Impact factor: 27.401

7.  High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers.

Authors:  Shinobu Umemura; Masatoshi Shirane; Susumu Takekoshi; Yutaka Tokuda; Kazushige Mori; Robert Y Osamura
Journal:  Oncol Lett       Date:  2010-03-01       Impact factor: 2.967

8.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

9.  Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.

Authors:  Yago Nieto; José Manuel Aramendía; Jaime Espinós; Susana De la Cruz; Oscar Fernández-Hidalgo; Marta Santisteban; Leyre Arbea; Javier Aristu; Rafael Martínez-Monge; Marta Moreno; Luis Pina; Josu Sola; Gerardo Zornoza; Fernando Martínez Regueira
Journal:  Cancer Chemother Pharmacol       Date:  2009-06-14       Impact factor: 3.333

10.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy).

Authors:  William A. Denny
Journal:  J Biomed Biotechnol       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.